Tin tức & Cập nhật

Radiologic imaging of high-risk cutaneous squamous cell carcinoma (sSCC) tumours displays unforeseen results such as local invasion and nodal metastasis, which result in changes in management in nearly half of these cases, reveals a study.

Treatment with abrocitinib or dupilumab results in the restoration of skin barrier function in patients with atopic dermatitis (AD), but these therapies show distinct proteomic impacts, according to a study.

Daily emollient application in infants helps reduce the cumulative incidence of atopic dermatitis throughout the 2 years of life and may be a feasible way to reduce its burden in communities, according to a study.

Several factors, including BMI and Charlson Comorbidity Index (CCI), can help predict treatment response among patients with psoriasis, suggests a study.

The selective oral Janus kinase 1 (JAK1) inhibitor ivarmacitinib helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adolescent and adult patients, while having a manageable safety profile, according to a phase III trial.

The BTK inhibitor rilzabrutinib helps lower disease activity in patients with chronic spontaneous urticaria (CSU) refractory to H1-antihistamines, while having an acceptable adverse event (AE) profile, according to the results of the phase II RILECSU study.

Combination treatment with the PI3Kδ inhibitor linperlisib plus the histone deacetylase inhibitor chidamide has demonstrated promising clinical activity in relapsed or refractory cutaneous T-cell lymphoma (CTCL) in a phase I study.